Trial Profile
Prospective, Open-label, Uncontrolled Clinical Trial to Assess the Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified With a Gamma-retroviral (rv) Vector Carrying COL17A1 cDNA for Restoration of Epidermis in Patients With Junctional Epidermolysis Bullosa
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 05 Sep 2022
Price :
$35
*
At a glance
- Drugs COL17A1 encoding stem cell therapy (Primary)
- Indications Epidermolysis bullosa
- Focus Adverse reactions; First in man
- Acronyms HOLOGENE17
- Sponsors Holostem Terapie Avanzate
- 18 Feb 2022 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: No patient ongoing (none completed the study). Changes to the viral vector ongoing.
- 10 Aug 2021 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
- 10 Aug 2021 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2022.